Home/Pipeline/R1065

R1065

IgA Nephropathy (IgAN)

DiscoveryActive (Global)

Key Facts

Indication

IgA Nephropathy (IgAN)

Phase

Discovery

Status

Active (Global)

Company

Harbour BioMed

About Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Metabolic Diseases

Other IgA Nephropathy (IgAN) Drugs

Drug	Company	Phase	Status
TARPEYO (Nefecon)	Calliditas Therapeutics	Approved	Commercial
TARPEYO (Nefecon) OLE	Calliditas Therapeutics	Phase 3	Active (Open-label Extension)
KP104	Kira Pharmaceuticals	Phase 2	Active
IFX-301	Infinimmune	Preclinical	Active
Atacicept	Vera Therapeutics	Phase 2b/3	Primary endpoint met in Phase 3 (ORIGIN 3) in June 2025
FILSPARI (sparsentan)	Travere Therapeutics	Approved	Commercial
Telitacicept	Vor Biopharma	BLA Submitted	Filed in China